



Amsterdam, September 2015

**Sanquin licenses its MHC IP portfolio to Immatix to support the development of onco-immunotherapies.**

Sanquin Blood Supply Foundation (Amsterdam, The Netherlands) has granted Immatix Biotechnologies GmbH (Tuebingen, Germany) a non-exclusive license to use its proprietary MHC T cell technologies to advance the development of immunotherapies in the field of oncology and infectious diseases.

Cytotoxic T cells in patients can kill cancerous and infected cells when their T Cell Receptor (TCR) recognizes disease specific peptides (antigens) presented by so-called major histocompatibility complex (MHC) on the infected/ tumor cell.

The technologies licensed to Immatix enable fast and simple generation of large series of peptide-MHC complexes for in vitro immunogenicity assays and for detecting the corresponding antigen-specific T cells in patient samples.